Jayesh P. Choksi
#882Chairman & Managing Director
70
Age
25y
Exp
25y
Tenure
7/10
Risk
🎓 B. Pharmacy · University of Mumbai (implied, B. Pharmacy)
🏛️ None
CompensationTBP
Personality
6
Open
7
Cons
5
Extr
5
Agre
4
Neur
Gufic BioScience
Healthcare · Small Cap
High Growth · Founder-Centric
About
Jayesh P. Choksi is the Chairman & Managing Director of Gufic BioScience, a Small Cap company in the Healthcare sector with a market cap of ₹3K Cr. A Visionary leader with 25 years of experience, he is known for intuition-driven decision-making and organic builder strategy. Aggressive focus on R&D-led growth and niche pharmaceutical segment expansion indicates a high appetite for product-centric risk.
FAQ
What is Jayesh P. Choksi's leadership style?
Jayesh P. Choksi is classified as a Visionary leader. He is intuition-driven in decision-making, with a category creator motivation and startup-speed pace of execution.
What is Jayesh P. Choksi's educational background?
Jayesh P. Choksi holds a B. Pharmacy from University of Mumbai (implied, B. Pharmacy).
Who is the CEO of Gufic BioScience?
Jayesh P. Choksi is the Chairman & Managing Director of Gufic BioScience. He has been with the company for 25 years and in the current role for 20 years.
Leadership DNA
ArchetypeVisionary
MotivationCategory Creator
CrisisSteady Hand
DecisionIntuition-Driven
GrowthOrganic Builder
PeopleRelationship Led
InnovationDisruptor
PaceStartup-Speed
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Aggressive focus on R&D-led growth and niche pharmaceutical segment expansion indicates a high appetite for product-centric risk.”
⚡ Crisis●●●○○
Gufic BioScience maintained its focus on core specialty drug manufacturing and R&D continuity during the pandemic-induced volatility.
🎯 Motivation●●●●○
Choksi has steered Gufic to pioneer niche segments like lyophilized injections and critical care products rather than just generic volume plays.
👥 People●●●○○
Gufic maintains a culture of long-term stability and internal continuity, reflecting the promoter-led management's personal oversight of operations.
📈 Growth●●●●○
The company's growth has been primarily driven by significant investments in in-house R&D and the expansion of its own manufacturing facilities.
💡 Innovation●●●●○
Gufic has carved a niche as a pioneer in lyophilization technology and has successfully launched unique, complex drug delivery systems like its proprietary anti-fungal and critical care products.
🏃 Pace●●●●○
The company maintains a high-velocity product pipeline, frequently securing patents and regulatory approvals for niche therapeutic segments in a short timeframe.
🌱 Purpose●●●○○
The company emphasizes its commitment to 'healing and helping' through its focus on affordable critical care and specialty segments, aligning with broader ESG reporting standards.
🏷️ Brand●●●●●
Gufic is widely recognized in the industry for its deep technical mastery of lyophilization and sterile manufacturing, rather than mass-market consumer branding.
🤝 Customer●●●●●
Gufic primarily operates as a manufacturer and supplier of specialty injectables and APIs to hospitals, clinics, and other pharmaceutical distributors.
💼 Employer●●●○○
As a specialized manufacturer in complex chemistry, the company is known for developing technical expertise in niche pharmaceutical manufacturing processes.
📋 Mandate
Transitioning from niche pharma to a broader specialty player requires R&D investment and portfolio transformation to capture market share.
🏢 Culture●●●○○
High promoter holding (77.5%) and active management by the Chairman indicates a top-down culture driven by founding family vision.
Financials
Revenue FY25₹746 Cr
PAT FY25₹70 Cr
Rev CAGR 5Y1.5%
OPM15.7%
NPM9.3%
ROE11.6%
ROCE15%
P/E57.8
Fwd P/E—
P/B4.6
D/E58.5
Promoter77.5%
Institutional3.6%
Mkt Cap₹3K Cr
Compensation
To Be Published
Data being verified from audited reports
